VIPRD
Virtual Institute on Poverty Related Diseases

29 April 2019

Novel antibody may suppress HIV for up to four months

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens. Results of Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV.